Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Enterprise Therapeutics logo — Dedicated to the development of novel therapies to improve t...

Enterprise Therapeutics

Dedicated to the development of novel therapies to improve the lives of patients with respiratory disease

Founded 2014 United Kingdom Brighton, United Kingdom 13 employees Series B Total: $68.80M Health Care, Health and Wellness

General Information

Company Name Enterprise Therapeutics
Founded Year 2014
Location United Kingdom Brighton, United Kingdom +1
Founders / Decision Makers
Team member Team member
Employees 13
Industries Health Care, Health and Wellness
Funding Stage Series B
Social

Get notified when Enterprise Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Enterprise Therapeutics

Enterprise Therapeutics is a UK-based drug discovery company founded in 2014, dedicated to developing innovative therapies for respiratory diseases. The company's focus lies in addressing conditions such as cystic fibrosis, asthma, and COPD, where mucus congestion in the lungs severely impacts patients' breathing and quality of life. By targeting the underlying mechanisms of mucus congestion, Enterprise Therapeutics aims to reduce lung infections and improve patient well-being. The leadership team boasts extensive expertise in drug discovery, development, respiratory biology, and ion channel pharmacology, effectively positioning the company to pioneer advancements in this critical field. Its recent £26.00M Series B investment on January 29, 2024, attracted a notable consortium of investors including Novartis Venture Fund, Forbion, IP Group, Versant Ventures, Epidarex Capital, and Panakes Partners, underlining the industry's confidence in the company's potential. Additionally, its close collaboration with the School of Life Sciences at the University of Sussex further enhances its research capabilities and potential for groundbreaking discoveries in Health Care and Health and Wellness industries.

Taxonomy: respiratory medicine, mucus congestion, COPD, asthma, cystic fibrosis, drug development, disease-modifying drugs, lung infections, quality of life, respiratory biology, ion channel pharmacology, University of Sussex, biopharmaceuticals

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Series B •••••• 6
Investor Investor Investor Investor Investor Investor
29 Jan 2024
Grant •••••• 1
Investor
15 Oct 2019
Series B •••••• 5
Investor Investor Investor Investor Investor
12 Apr 2018
Grant •••••• 1 •••• •••• 05 Apr 2017
Venture Round •••••• 2
Investor
•••• •••• 		10 Nov 2016

View All 7 Funding Rounds

Latest News

View All
Fintech on the lead again - HSBC Innovation Banking and Dealroom's UK Innovation Update — Tech
Fintech on the lead again - HSBC Innovation Banking and Dealroom's UK Innovation Update
Tech Apr 17, 2024

Enterprise Therapeutics Alternatives & Competitors

Enterprise Therapeutics vs
Pulmocide
Pulmocide United Kingdom

Developing best-in-class inhaled medicines for targeted treatment of life-threatening respiratory di...

Series C
25 employees
Biotechnology, Health Care
Enterprise Therapeutics vs
Enalare Therapeutics Inc.
Enalare Therapeutics Inc. United States

Developing novel therapies for life-threatening acute respiratory and critical care conditions.

Unknown
10 employees
Biopharma, Biotechnology
Enterprise Therapeutics vs
Strados Labs
Strados Labs United States

Digital Lung Acoustics for Better Insight | Cough, Wheeze, Crackles

Series Unknown
47 employees
AI, Digital Health
Also compare with: Enterprise Therapeutics vs Verona Pharma Verona Pharma

FAQ About Enterprise Therapeutics

Dedicated to the development of novel therapies to improve the lives of patients with respiratory disease
Enterprise Therapeutics was founded in 2014.
Enterprise Therapeutics is headquartered in Brighton, United Kingdom.
Enterprise Therapeutics operates in the following industries: Health Care, Health and Wellness.
Enterprise Therapeutics has approximately 13 employees.
Enterprise Therapeutics has completed 7 funding rounds, raising a total of $68.80M. The latest funding stage is Series B.
Top alternatives and competitors to Enterprise Therapeutics include Pulmocide, Enalare Therapeutics Inc., Strados Labs, Inhalon Biopharma, Star Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Enterprise Therapeutics and Pulmocide are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Enterprise Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy